A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

John C. Byrd, John M. Pagel, Farrukh T. Awan, Andres Forero, Ian W. Flinn, Delva P. Deauna-Limayo, Stephen E. Spurgeon, Leslie A. Andritsos, Ajay K. Gopal, John P. Leonard, Amy J. Eisenfeld, Jeannette E. Bannink, Scott C. Stromatt, Richard R. Furman

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Fingerprint Dive into the research topics of 'A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds